Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,117 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Disease Clear all
Recruiting Not applicable Interventional

Vestibular Therapy in Alzheimer's Disease

NCT03799991
View directory record Official record
Conditions
Vestibular Diseases, Vestibular Disorder, Alzheimer Disease
Interventions
Vestibular physical therapy, Active control
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE)

NCT04165213
View directory record Official record
Conditions
Frontotemporal Dementia, Dementia, Multi-Infarct Dementia, Vascular Dementia, Mixed Dementia, Alzheimer Disease, Lewy Body Disease, Pick Disease, Neurocognitive Disorders
Interventions
Care of Older Persons in their Environment (COPE) online module training
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 100 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00556660
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] AV-151
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 26, 2026, 4:02 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

NCT06126224
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
70
States / cities
Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Riluzole in Mild Alzheimer's Disease

NCT01703117
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 26, 2026, 4:02 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT02245568
View directory record Official record
Conditions
Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia
Interventions
LMTM
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Not listed
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Phoenix, Arizona • Fountain Valley, California • Laguna Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)

NCT03438604
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil TDS
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 26, 2026, 4:02 AM EDT
Active, not recruiting Not applicable Interventional

Stress and Blood Pressure Management for Caregivers

NCT05734638
View directory record Official record
Conditions
Hypertension, Stress, Psychological
Interventions
MIM-DASH, MIM Only, DASH Only
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
40 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Online Caregiver Psychoeducation and Support for Alzheimer's

NCT00416078
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
caregiver website support, caregiver brief supportive phone calls
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 95 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 3 Interventional

VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)

NCT00056225
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Folate, Vitamin B6, Vitamin B12
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Stamford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558

NCT01217021
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F] MNI-558
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Not applicable Interventional

Assessing an Intergenerational Music Program Delivered by Adolescents to Older Adults With Declining Cognition

NCT04645017
View directory record Official record
Conditions
Dementia Alzheimers
Interventions
Intergenerational Music Program
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 26, 2026, 4:02 AM EDT
Not listed No phase listed Observational

Evidence Amyloid Scan EEG Study

NCT03644043
View directory record Official record
Conditions
Alzheimer Disease, Dementia Frontal, Mild Cognitive Impairment
Interventions
EEG scan
Device
Lead sponsor
Metabolic Therapy Inc.
Other
Eligibility
60 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 26, 2026, 4:02 AM EDT
Active, not recruiting No phase listed Observational

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

NCT02951598
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Florbetapir F 18 PET Scan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
77
States / cities
Anaheim, California • Imperial, California • Irvine, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

NCT02240693
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Orange, California • Sherman Oaks, California • West Palm Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease

NCT03402659
View directory record Official record
Conditions
Alzheimer Disease
Interventions
neflamapimod, placebo
Drug · Other
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Long Beach, California • San Diego, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 4 Interventional Results available

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

NCT03703856
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memantine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 83 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 26, 2026, 4:02 AM EDT
Not yet recruiting Phase 1 Interventional

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

NCT06600880
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 26, 2026, 4:02 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

NCT07787169
View directory record Official record
Conditions
Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Augmenting Flortaucipir Dosimetry Estimates

NCT02336360
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

NCT03019536
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

NCT00151502
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
40
States / cities
Sun City, Arizona • Fresno, California • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 26, 2026, 4:02 AM EDT
Completed Not applicable Interventional Results available

Version 2 of the Smoking Cessation Smartphone App "Smiling Instead of Smoking" (SiS)

NCT03951766
View directory record Official record
Conditions
Smoking Cessation, Smoking, Tobacco
Interventions
Smiling Instead of Smoking (SiS) App Version 2
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 26, 2026, 4:02 AM EDT